Marksans Pharma (MARKSANS) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue grew 18.1% year-over-year to INR 590.6 crore, with EBITDA up 26% and PAT up 26.4%, driven by new product launches, increased market share, and improved customer penetration, especially in the U.S. and U.K.

• U.S. remains a strategic focus, with expectations for better performance in upcoming quarters despite mixed demand and stable pricing pressure.

• The company targets INR 3,000 crore revenue within the next two years, leveraging new facility ramp-up and product launches.

• Shipments from the new facility have commenced, supporting optimism for stronger future quarters.

• Board strengthened with reappointments, maintaining robust governance.

Financial highlights

• Operating revenue for Q1 FY25 was INR 590.6 crore, up 18.1% year-over-year; consolidated revenue reached ₹5,906.18 million.

• U.S. and North America revenue grew 29.8% YoY to INR 251 crore; U.K. and EU up 11.3% to INR 251.5 crore; Australia/NZ up 12% to INR 65.6 crore.

• Gross profit rose 27.8% YoY to INR 329 crore; gross margin increased by 420 bps to 55.7%.

• EBITDA was INR 128.4 crore, up 26% YoY; EBITDA margin at 21.7%.

• Profit after tax reached INR 89.1 crore, up 26.4% YoY; EPS at INR 2.

Outlook and guidance

• Management expects continued growth, with the new facility contributing more significantly from Q3 onwards.

• U.S. and U.K. markets are expected to drive growth, with U.S. leading in absolute terms.

• Gross margin improvement is seen as sustainable barring major geopolitical or freight disruptions.

• Targeting INR 3,000 crore revenue within two years, supported by robust order book and contract visibility.

• Focus on disciplined capital allocation and M&A, especially in Europe.